The breadth of data showcases the continued impact of Merck’s portfolio of oncology medicines and the potential of Merck's innovative oncology pipeline. RAHWAY, N.J.-( BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that research spanning 16 different cancer types will be presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, France from Sept.